https://orcid.org/0000-0002-2338-513X
Figures & data
Table 1. Baseline demographics and disease characteristics.
Figure 1. Patient disposition. HMA: hypomethylating agent; LDAC: low-dose cytarabine.
Figure 2. Overview of systemic therapies received in the first line and second line of treatment. aOther includes cytarabine, aclarubicin, G-CSF (CAG regimen), enocitabine, venetoclax, or combination therapies. BSC: best supportive care; CAG: cytarabine, aclarubicin, and granulocyte colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; HMA: hypomethylating agents; LDAC: low-dose cytarabine.
Figure 3. KM curves for OS in patients who received HMA, LDAC, other systemic therapies and BSC. BSC: best supportive care; CI: confidence interval; HMA: hypomethylating agent; KM: Kaplan–Meier; LDAC: low-dose cytarabine; OS: overall survival.
Figure 4. KM curves for (A) PFS and (B) TTF in patients who received HMA, LDAC, other systemic therapies and BSC. BSC: best supportive care; CI: confidence interval; HMA: hypomethylating agent; KM: Kaplan–Meier; LDAC: low-dose cytarabine; PFS: progression-free survival; TTF: time to treatment failure.
Table 2. Outcomes of first-line systemic treatment.
Data availability statement
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g. protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.